Caris Net Income From Continuing Ops from 2010 to 2026

CAI Stock  USD 18.20  0.56  3.17%   
Caris Life's Net Loss is decreasing with very volatile movements from year to year. Net Loss is predicted to flatten to about -340.4 M. For the period between 2010 and 2026, Caris Life, Net Loss quarterly trend regression had median of (320,827,000) and r-value of (0.05). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-324.2 M
Current Value
-340.4 M
Quarterly Volatility
12.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Caris Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Caris Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 33.1 M or Total Revenue of 497.8 M, as well as many indicators such as Price To Sales Ratio of 16.34, Dividend Yield of 0.0333 or Days Sales Outstanding of 175. Caris financial statements analysis is a perfect complement when working with Caris Life Valuation or Volatility modules.
  
Build AI portfolio with Caris Stock
Check out the analysis of Caris Life Correlation against competitors.
The Net Income From Continuing Ops trend for Caris Life Sciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Caris Life is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Caris Life's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Caris Life Sciences over the last few years. It is Caris Life's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Caris Life's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Very volatile
   Net Income From Continuing Ops   
       Timeline  

Caris Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(321,094,804)
Coefficient Of Variation(3.76)
Mean Deviation5,021,913
Median(320,827,000)
Standard Deviation12,073,578
Sample Variance145.8T
Range59.5M
R-Value(0.05)
Mean Square Error155.1T
R-Squared0
Significance0.85
Slope(120,551)
Total Sum of Squares2332.3T

Caris Net Income From Continuing Ops History

2026-340.4 M
2025-324.2 M
2024-281.9 M
2023-341.4 M

About Caris Life Financial Statements

Investors use fundamental indicators, such as Caris Life's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Caris Life's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-324.2 M-340.4 M

Currently Active Assets on Macroaxis

When determining whether Caris Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Caris Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Caris Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Caris Life Sciences Stock:
Check out the analysis of Caris Life Correlation against competitors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is there potential for Trading Companies & Distributors market expansion? Will Caris introduce new products? Factors like these will boost the valuation of Caris Life. Projected growth potential of Caris fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Caris Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.25)
Revenue Per Share
3.18
Quarterly Revenue Growth
0.499
The market value of Caris Life Sciences is measured differently than its book value, which is the value of Caris that is recorded on the company's balance sheet. Investors also form their own opinion of Caris Life's value that differs from its market value or its book value, called intrinsic value, which is Caris Life's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Caris Life's market value can be influenced by many factors that don't directly affect Caris Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Caris Life's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Caris Life should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Caris Life's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.